In a report released today, Jason Bednar from Piper Sandler reiterated a Buy rating on MDxHealth S.A. Sponsored ADR (MDXH – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $4.28.
Bednar covers the Healthcare sector, focusing on stocks such as Align Tech, Henry Schein, and Cooper Co. According to TipRanks, Bednar has an average return of -4.9% and a 40.00% success rate on recommended stocks.
MDxHealth S.A. Sponsored ADR has an analyst consensus of Strong Buy, with a price target consensus of $6.33.
See the top stocks recommended by analysts >>
The company has a one-year high of $7.58 and a one-year low of $2.15. Currently, MDxHealth S.A. Sponsored ADR has an average volume of 73.19K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MDxHealth S.A. Sponsored ADR (MDXH) Company Description:
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company’s patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
